We present amale with neonatal convulsions; structural brain anomaly, hyperglycinemia inCSF/plasma, with ALDH7A1 Compound heterozygote mutation.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Pyridoxine-dependent epilepsy (PDE) is a rare but an important condition,since early diagnosis and treatment result in normal or near normalpsychomotor development.
📊
Key Findings & Data:It is caused by mutations in the Antiquitin(ALDH7A1) gene.
💡
Conclusion & Impact:We present amale with neonatal convulsions; structural brain anomaly, hyperglycinemia inCSF/plasma, with ALDH7A1 Compound heterozygote mutation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Pyridoxine-dependent epilepsy (PDE) is a rare but an important condition,since early diagnosis and treatment result in normal or near normalpsychomotor development. It is caused by mutations in the Antiquitin(ALDH7A1) gene. Different clinical findings may appear in the deficiency ofpyridoxine, which is the cofactor of many enzymes. A wide variety of clinicaland laboratory findings can cause confusion during diagnosis. We present amale with neonatal convulsions; structural brain anomaly, hyperglycinemia inCSF/plasma, with ALDH7A1 Compound heterozygote mutation.
🔖
Cite This Article
TEKİN, H. G., DEMİR, M., AKTAN, G., TEKGÜL, H., GÖKBEN, S. (2019). The case of pyridoxine dependent epilepsy misdiagnosed as non-ketotic hyperglycinemia. Turkish Journal of Pediatrics, Cilt: 61 - Sayı: 4, 599–603. https://ajindex.com/articles/412099
Stockler S, Plecko B, Gospe SM Jr, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011; 104: 48-60
Bass NE, Wyllie E, Cohen B, Joseph SA. Pyridoxinedependent epilepsy: the need for repeated pyridoxine trials and the risk of severe electrocerebral suppression with intravenous pyridoxine infusion. J Child Neurol 1996; 11: 422-424
Grillo E, da Silva RJ, Barbato JH Jr. Pyridoxinedependent seizures responding to extremely lowdose pyridoxine. Dev Med Child Neurol 2001; 43: 413-415
Plecko B, Stöckler S. Vitamin B6 dependent seizures. Can J Neurol Sci 2009; 36(Suppl 2): S73-S77
Aliefendioğlu D, Aslan AT, Coskun T, Dursun A, Cakmak FN, Kesimer M. Transient nonketotic hyperglycinemia: two case reports and literature review. Pediatr Neurol 2003; 28: 151-155
Tada K, Kure S, Takayanagi M, Kume A, Nrisawa K. Non-ketotic hyperglycinemia: A life-threatening disorder in the neonate. Early Hum Dev 1992; 29: 75-81
Maeda T, Inutsuka M, Goto K, Izumi T. Transient nonketotic hyperglycinemia in an asphyxiated patient with pyridoxine-dependent seizures. Pediatr Neurol 2000; 22: 225-227
Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiencey). Brain 2010; 133(Pt 7): 2148-2159
Van Karnebeek CD, Tiebout SA, Niermeijer J, et al. Pyridoxine-dependent epilepsy: an expanding clinical spectrum. Pediatr Neurol 2016; 59: 6-12
Stöckler-Ipsiroglu S, Van Karnebeek CDM. Pyridoxine and pyridoxal-phosphate dependent epilepsies. In: Hoffmann GF, Blau N, (eds). Congential Neurotransmitter Disorders. Nova Science Publishers; 2014: 149-166
Mercimek-Mahmutoglu S, Horvath GA, CoulterMackie M, et al. Profound neonatal hypoglycemia and lactic acidosis caused by pyridoxine-dependent epilepsy. Pediatrics 2012; 129: e1368-e1372
Pacifici GM. Clinical pharmacology of phenobarbital in neonates: effects, metabolism and pharmacokinetics. Curr Pediatr Rev 2016; 12: 48-54
Tekgul H, Serdaroğlu G, Karapinar B, et al. Vigabatrin caused rapidly progressive deterioration in two cases with early myoclonic encephalopathy associated with nonketotic hyperglycinemia. J Child Neurol 2006; 21: 82-84